Financial Performance
5Y price score: 42
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 127.5%
US$ Per
Share
By default your notes are visible only to you.
239.5
52-week range
315.4
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
12.3 %
Dividend Yield TTM
2.2 %
Market cap $
$ 73,456
Price / Earnings TTM
11.5
Price / Book TTM
1.7
PEG TTM
0.1
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
(1.1) %
43.9 %
127.5 %
Free cash flow per share growth
(0.3) %
25.5 %
239.3 %
Earnings per share growth
82.9 %
(3.4) %
175.7 %
Founded: 1,982
Employees: 71,295
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Jul 30, 2026)
1) Strategic Direction & Leadership - Brian Evanko, the new CEO, emphasizes a strong strategic direction focused on affordability, personalized experiences, and actionable insights in healthcare. - The leadership team is experienced and committed to leveraging data and technology, including AI, to enhance customer experiences and improve health outcomes. - The company is positioned to innovate and drive change in a dynamic healthcare landscape.
2) Financial & Segment Results - Cigna reported total revenues of $71.7 billion and adjusted earnings per share (EPS) of $7.78 for Q2 2026. - Evernorth's revenues grew 6% YoY to $61.5 billion, with pretax adjusted earnings of $1.7 billion. Specialty & Care Services saw a 22% YoY growth in pretax adjusted earnings to $1.1 billion. - Cigna Healthcare's revenues increased 10% YoY to $11.8 billion, with pretax adjusted earnings of $1.3 billion and a medical care ratio (MCR) of 84.5%.
3) Challenges & Headwinds - The company faces economic pressures and geopolitical uncertainties, impacting healthcare affordability and customer expectations. - Growth in GLP-1 prescriptions has moderated, affecting the pharmacy benefit services segment. - The exit from the ACA exchange business may lead to stranded overhead and a modest capital release, but overall, the impact is manageable.
4) Operational & Product Plans - Cigna is investing in AI and technology to enhance customer support and streamline processes, such as the Pharmacy Forward initiative aimed at improving access to specialty medications. - The Signature Pharmacy Benefit model is being developed for a broader market launch in 2028, with strong interest from clients. - Cigna continues to focus on expanding its Specialty & Care Services, particularly through partnerships with health systems and hospitals.
5) Guidance & Outlook / Investor Angle - Cigna raised its full-year adjusted EPS guidance to at least $30.45, reflecting strong performance in the first half of 2026. - The company anticipates continued growth in Specialty & Care Services, while managing expectations for the Pharmacy Benefit Services segment due to shifting dynamics. - Upcoming Investor Day in September will provide further insights into long-term strategies and growth opportunities.
Bottom line: Cigna's strong Q2 performance, strategic focus on innovation and affordability, and raised earnings guidance position the company favorably for shareholders, despite facing some operational challenges and market dynamics.
Annual Reports, Presentations And IR Contacts
Go to the websiteCigna — Financial Overview, Stock Price, Market Cap
Cigna is a company. Founded in 1982. As of August 14, 2026, the company's market capitalization is $73456212703 with a current stock price of $277.99.